Search results for "phosphonate"

showing 10 items of 372 documents

CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma

2011

Osteonecrosis of the jaw is an uncommon but potentially serious complication of bisphosphonate therapy in multiple myeloma. Previous studies showed that the presence of one or two minor alleles of the cytochrome P450, subfamily 2C polypeptide 8 gene (CYP2C8) polymorphism rs1934951 was an independent prognostic marker associated with development of osteonecrosis of the jaw in multiple myeloma patients treated with bisphosphonates. The aim of this study was to validate the frequency of SNP rs193451 in 79 patients with multiple myeloma. In 9 (22%) patients developing osteonecrosis of the jaw, a heterozygous genotype was found, in contrast with those who did not develop osteonecrosis of the jaw…

AdultMalemedicine.medical_specialtyPathologyCYP2C8Genotypemedicine.medical_treatmentONJGastroenterologyPolymorphism Single NucleotideCytochrome P-450 CYP2C8stomatognathic systemInternal medicineGenotypemedicineSNPHumansAllelebisphosphonatesMultiple myelomaAllelesAgedAged 80 and overBisphosphonate-associated osteonecrosis of the jawbusiness.industryHematologyBisphosphonateMiddle Agedmedicine.diseasemultiple myelomastomatognathic diseasesBisphosphonate-Associated Osteonecrosis of the JawFemaleBrief ReportsAryl Hydrocarbon HydroxylasesOsteonecrosis of the jawComplicationbusinessMultiple Myeloma
researchProduct

An analysis of oral biopsies extracted from 1995 to 2009, in an oral medicine and surgery unit in Galicia (Spain)

2011

Objective: To conduct an analysis of the frequency of oral lesions in biopsies over a 14-year period in the Oral Medicine, Oral Surgery and Implantology Unit. Material and Methods: We conducted a retrospective study of biopsies removed from 1995-2009, recording data regarding age, sex, location of the lesions, biopsy types, anatomical and pathological diagnosis and definitive diagnosis. Results: Of the 562 patients studied, the average age was 51.8 years, with a standard deviation of 18.5 (range 5-96). The distribution by sex was 318 (56.6%) women and 244 (43.4%) men. The most common diagnostic category was mucosal pathologies in 37.9% of cases, followed by odontogenic cysts in 27.8%. Malig…

AdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.medical_treatmentBiopsyOral MedicineMalignancyYoung AdultBiopsyMedicineHumansYoung adultChildGeneral DentistryPathologicalAgedRetrospective StudiesAged 80 and overMouthOral Medicine and Pathologymedicine.diagnostic_testbusiness.industryRetrospective cohort studyBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]SurgeryOdontogenicOtorhinolaryngologySpainChild PreschoolUNESCO::CIENCIAS MÉDICASSurgeryResearch-ArticleFemalebusinessMouth DiseasesOral medicineHospital UnitsSurgery Department Hospital
researchProduct

Evaluation of socket healing in patients undergoing bisphosphonate therapy: experience of a single Institution

2012

Objective: To assess the clinical features of exodontias performed in cancer patients who have been receiving intravenous bisphosphonates (BPs). Study Design: This is a retrospective cohort study using a sample of 20 patients receiving BPs who had 62 teeth extracted. An univariate analysis was applied to calculate socket healing time (HT), comparing among exodontias performed according to cause, such as periodontal disease or caries, type of BP, and use of corticosteroid. In order to analyze the influence of each variable on HT, multiple statistical analyses were performed through logistic multiple regression. Results: From the 62 tooth extractions performed, 5 exodontias had evolved to 4 s…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentDentistryOdontologíaCohort StudiesmedicineHumansTooth SocketGeneral DentistryDental alveolusAgedRetrospective StudiesAged 80 and overUnivariate analysisWound HealingDiphosphonatesbusiness.industryCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryOtorhinolaryngologyTooth ExtractionUNESCO::CIENCIAS MÉDICASCorticosteroidSurgeryFemaleResearch-ArticleOdontostomatology for the Disabled or Special PatientsbusinessOsteonecrosis of the jawCohort study
researchProduct

Case series of 589 tooth extractions in patients under bisphosphonates therapy. Proposal of a clinical protocol supported by Nd: YAG low-level laser …

2013

Objective: Trauma during dental surgery is a predisposing factor for bisphosphonates (BP)-related osteonecrosis of the jaws (BRONJ). However, about 40% of cases of BRONJ are not related to dental invasive procedures, being probably associated to endodontic or periodontal infections. Extraction of non-treatable teeth is considered a reliable choice, to improve symptoms and to reduce the risk of BRONJ. Here we report our experience of tooth extractions in patients under oral or intravenous BP therapy. Study Design: Two-hundred and seventeen patients (38 males, 179 females; mean age 68.72 ± 11.26 years, range 30 to 83 years) under BP therapy received 589 tooth extractions at the Unit of Oral M…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentOsteoporosisAntibioticsDentistryOdontologíaLasers Solid-StatePostoperative ComplicationsClinical ProtocolsmedicineHumansLow-Level Light TherapyDental CareGeneral DentistryMultiple myelomaLow level laser therapyAgedAged 80 and overBisphosphonate-associated osteonecrosis of the jawDiphosphonatesbusiness.industryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludSurgerystomatognathic diseasesOtorhinolaryngologyRheumatoid arthritisDental surgeryTooth ExtractionUNESCO::CIENCIAS MÉDICASResearch-ArticleBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryOral SurgerybusinessOral medicine
researchProduct

Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws.

2011

Osteonecrosis of the jaws is a clinical entity described and linked to treatment with bisphosphonates in 2003. Its real incidence is unknown and it could increase due to the large number of patients treated with these drugs, and its cumulative effect on the bone. State of the art knowledge regarding its etiopathogeny, clinical course and suitable treatments is limited. Objectives: To study the clinical characteristics of 44 patients with bisphosphonate-related osteonecrosis of the jaws and the state of their bone mineral metabolism: bone remodeling state, prevalence of fractures, bone mineral density study, and assessment of the different treatment strategies. Design of the Study: Observati…

AdultMalemedicine.medical_treatmentOsteoporosisDentistryOdontologíaBone and BonesBone remodelingBreast cancermedicineHumansProspective StudiesProspective cohort studyGeneral DentistryAgedBone mineralAged 80 and overBisphosphonate-associated osteonecrosis of the jawOral Medicine and Pathologybusiness.industryIncidence (epidemiology)BisphosphonateMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la saludOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticlebusinessMedicina oral, patologia oral y cirugia bucal
researchProduct

Demographic and behavioural profiles of patients with common oral mucosal lesions by a homogeneity analysis

2012

Objective: The aim of this study is to assess the main oral mucosal lesions (OMLs) within a hospital base and to provide an anamnestic, diagnostic model based on homogeneity analysis of some variables. Methods: The demographic and behavioural data (i.e. gender, age, smoking status, alcohol consumption and therapeutic drug usage) of 1753 patients with at least one OML were considered. Multiple correspondence analysis (MCA) and multivariate tests of the simultaneous marginal homogeneity hypothesis (SMH) were used to analyse the evidence of any differences between the demographic and behavioural profiles relating to OMLs diagnoses. Statistical significance of P<0.05 was chosen. Results: With r…

AdultMalesquamous cell carcinomaAdolescentAlcohol DrinkingHealth BehaviorBurning Mouth SyndromeSettore MED/01 - Statistica MedicaYoung AdultSex FactorsDrug TherapySettore MED/28 - Malattie Odontostomatologichemarginal homogeneity hypothesisoral mucosal lesionHumansBMSChildAgedDemographyAged 80 and overhalitosiBRONJSmokingAge FactorsHalitosisMiddle AgedItalyleukoplakiaChild PreschoolCarcinoma Squamous CellBisphosphonate-Associated Osteonecrosis of the JawFemaleMouth NeoplasmsStomatitis AphthousLeukoplakia OralMouth DiseasesRAS
researchProduct

Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases.

2006

Background: The effects of the bisphosphonate derivative zoledronic acid (ZA) on the > circulating levels of matrix metalloproteinase-2 (MMP-2), matrix metallo-proteinases-9 > (MMP-9), cathepsin B (Cath B) and urokinase-type plasminogen activator (uPA) in > patients with bone metastasis (BMTS) and the possible correlation with the symptomatic > response induced by this drug in these patients were evaluated. Patients and Methods: > Proteinase levels were determined by enzyme-linked immunosorbent assay (ELISA) in the > plasma of 30 patients with painful bone metastases from breast or prostate cancer > undergoing multiple treatment with ZA (4 mg i.v., every 4 weeks). Healthy subjects > (HS) of…

Aged 80 and overMaleBone Density Conservation AgentsDiphosphonatesZoledronic > acidImidazolesProstatic NeoplasmsBone NeoplasmsBreast NeoplasmsMiddle AgedProteinaseZoledronic AcidCathepsin BMatrix > metalloproteinase-9Matrix Metalloproteinase 9Matrix metalloproteinase-2Bone metastasiBisphosphonates; Bone metastasis; Cathepsin B; Matrix metalloproteinase-2; Matrix > metalloproteinase-9; Proteinases; Urokinase-type plasminogen activator; Zoledronic > acidHumansMatrix Metalloproteinase 2BisphosphonateFemaleUrokinase-type plasminogen activatorAged
researchProduct

Novel formulations of oral bisphosphonates in the treatment of osteoporosis

2022

AbstractOral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still mainta…

AgingDiphosphonatesAlendronateAlendronate/adverse effects610 Medicine & healthRisedronic Acid/therapeutic useDiphosphonates/adverse effectsFractures BoneHumansOsteoporosisAlendronate Bisphosphonates Fragility fracture Osteoporosis Risedronate TherapyGeriatrics and Gerontology610 Medizin und GesundheitBoneFracturesRisedronic AcidOsteoporosis/drug therapy
researchProduct

Aminobisphosphonate-activated γδ T cells in immunotherapy of cancer: doubts no more

2008

BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic …

Aminobisphosphonate Gamma delta T cells cancermedicine.medical_treatmentT cellClinical BiochemistryReceptors Antigen T-CellAntineoplastic AgentsModels BiologicalInterleukin 21Immune systemAntigenT-Lymphocyte SubsetsIn vivoNeoplasmsDrug DiscoveryAnimalsHumansCytotoxic T cellMedicinePharmacologyClinical Trials as TopicDiphosphonatesbusiness.industryT-cell receptorReceptors Antigen T-Cell gamma-deltaImmunotherapyKiller Cells Naturalmedicine.anatomical_structureImmune SystemImmunologyInterleukin-2ImmunotherapybusinessImmunologic MemoryExpert Opinion on Biological Therapy
researchProduct

Nanoparticular bisphosphonate to selectively target and repolarize liver macrophages for efficient anti-tumour responses

2019

Anti tumourbusiness.industrymedicine.medical_treatmentCancer researchMedicineBisphosphonatebusinessZeitschrift für Gastroenterologie
researchProduct